Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055529 | 0.82 | KDM4E (0.49) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6342286 | 0.81 | ADORA2A (0.49) | ADORA1ADORA2AADORA2BHTTKDM4E | |
| SCHEMBL421370 | 0.80 | ADORA1 (0.51) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL19018356 | 0.76 | ADORA1 (0.47) | ADORA1ADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL6055520 | 0.75 | L3MBTL1 (0.43) | KDM4EALDH1A1SMN1; SMN2PTGS2MEN1 | |
| SCHEMBL12679716 | 0.74 | ALDH1A1 (0.52) | ADORA1ADORA2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9537241 | 0.72 | ADORA1 (0.38) | ADORA1ADORA2AADORA2BHTTALDH1A1 | |
| SCHEMBL6055534 | 0.72 | HTT (0.49) | ADORA1ADORA2AADORA2BHTTKDM4E | |
| SCHEMBL6343690 | 0.72 | CD274 (0.42) | ADORA1ADORA2AHTTKDM4EALDH1A1 | |
| SCHEMBL6344957 | 0.72 | HPGD (0.58) | HTTKDM4EALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075352-A1 | 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-07 | — | — | US | disclosed |
| US-6759410-B1 | CYTOKINE SUPPRESSIVE ANTIINFLAMMATORIES | SMITHLINE BEECHAM CORPORATION | 2004-07-06 | — | — | US | disclosed |
| EP-1248624-A4 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1248624-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001037837-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075352-A1 | 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors | MAPKAPK2, MAPKAPK3, CREBBP | ADORA1 4400/4885ADORA2A 3441/4885ADORA2B 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.